Su médico decidirá entonces si se aumenta a la dosis habitual de mantenimiento de 80Se debería comenzar Strattera con una dosis diaria total de 40 mg durante un mínimo de 7 días. Patients who were pre-pubertal at the start of treatment (girls ≤8 years old, boys ≤9 years old) gained an average of 2.1 kg and 1.2 cm less than predicted after three years. Dosing of children and ad… Strattera should be initiated at a total daily dose of 40 mg. The parents or guardians of pediatric patients taking STRATTERA and adult patients taking STRATTERA should be instructed that priapism requires prompt medical attention.Patients should be instructed to consult a physician if they are taking or plan to take any prescription or over-thecounter medicines, dietary supplements, or herbal remedies.Patients should be instructed to consult a physician if they are nursing, pregnant, or thinking of becoming pregnant while taking STRATTERA.If patients miss a dose, they should be instructed to take it as soon as possible, but should not take more than the prescribed total daily amount of STRATTERA in any 24-hour period.Patients should be instructed to use caution when driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected by atomoxetine.Atomoxetine HCl was negative in a battery of genotoxicity studies that included a reverse The metabolite N-desmethylatomoxetine HCl was negative in the Ames Test, mouse lymphoma assay, and unscheduled DNA synthesis test.Atomoxetine HCl did not impair fertility in rats when given in the diet at doses of up to 57 mg/kg/day, which is approximately 6 times the maximum human dose on a mg/mPregnant rabbits were treated with up to 100 mg/kg/day of atomoxetine by gavage throughout the period of organogenesis. People with reduced activity in this pathway (PMs) have higher plasma concentrations of atomoxetine compared with people with normal activity (EMs). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.With other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (including In extensive metabolizers (EMs), inhibitors of CYP2D6 (e.g., paroxetine, Because of possible effects on blood pressure, STRATTERA should be used cautiously with STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.Coadministration of STRATTERA (60 mg BID for 12 days) with midazolam, a model compound for CYP3A4 metabolized drugs (single dose of 5 mg), resulted in 15% increase in AUC of midazolam. For patients with severe HI (Child-Pugh Class C), initial dose and target doses should be reduced to 25% of normal [see In children and adolescents up to 70 kg body weight administered strong CYP2D6 inhibitors, e.g., paroxetine, In children and adolescents over 70 kg body weight and adults administered strong CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and quinidine, STRATTERA should be initiated at 40 mg/day and only increased to the usual target dose of 80 mg/day if symptoms fail to improve after 4 weeks and the initial dose is well tolerated.Each capsule contains atomoxetine HCl equivalent to 10 mg (Opaque White, Opaque White), 18 mg (Gold, Opaque White), 25 mg (Opaque Blue, Opaque White), 40 mg (Opaque Blue, Opaque Blue), 60 mg (Opaque Blue, Gold), 80 mg (Opaque Brown, Opaque White), or 100 mg (Opaque Brown, Opaque Brown) of atomoxetine.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USA.

STRATTERA should be initiated at a total daily dose of approximately 0.5 mg/kg and increased after a minimum of 3 days to a target total daily dose of approximately 1.2 mg/kg administered either as a single daily dose in the morning or as evenly … No additional benefit has been demonstrated for doses higher than 1.2 mg/kg/day [see The total daily dose in children and adolescents should not exceed 1.4 mg/kg or 100 mg, whichever is less.STRATTERA should be initiated at a total daily dose of 40 mg and increased after a minimum of 3 days to a target total daily dose of approximately 80 mg administered either as a single daily dose in the morning or as evenly divided doses in the morning and late afternoon/early evening. In clinical trials with children and adolescents, administration of STRATTERA with food resulted in a 9% lower Cmax.The steady-state volume of distribution after intravenous administration is 0.85 L/kg indicating that atomoxetine distributes primarily into total body water. Because atomoxetine is highly protein-bound, STRATTERA is contraindicated in patients known to be hypersensitive to atomoxetine or other constituents of the product [see In clinical trials, STRATTERA use was associated with an increased risk of mydriasis and therefore its use is not recommended in patients with narrow angle Serious reactions, including elevated blood pressure and tachyarrhythmia, have been reported in patients with pheochromocytoma or a history of pheochromocytoma who received STRATTERA. Dosage adjustment of STRATTERA may be necessary when coadministered with potent CYP2D6 inhibitors (e.g., paroxetine, Physicians should instruct their patients to read the Medication Guide before starting therapy with STRATTERA and to reread it each time the prescription is renewed.Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with STRATTERA and should counsel them in its appropriate use.

Asimismo debe esperar al menos 14 días después de terminar su tratamiento con Strattera antes de tomar un IMAO.tiene una enfermedad ocular llamada glaucoma de ángulo estrecho (aumento de la presión en los ojos).tiene problemas graves de corazón que pueden empeorar por un incremento en la frecuencia cardíaca y/o en la presión sanguínea, lo cual puede ocurrir con Strattera.tiene problemas graves en los vasos sanguíneos de su cerebro, tales como un derrame cerebral, parte de un vaso sanguíneo inflamado y debilitado (aneurisma) o vasos sanguíneos estrechos u obstruidos.tiene un tumor de su glándula adrenal (feocromocitoma).No tome Strattera si le aplica alguno de los casos anteriores.